Sökning: WFRF:(Remes Kari) >
Carfilzomib and dex...
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
-
- Gregersen, Henrik (författare)
- Aalborg Univ Hosp, Dept Haematol, Molleparkvej 4, DK-9000 Aalborg, Denmark.
-
- Peceliunas, Valdas (författare)
- Vilnius Univ, Hosp Santaros Klin, Dept Haematol, Vilnius, Lithuania.
-
- Remes, Kari (författare)
- Turku Univ Hosp, Dept Haematol, Turku, Finland.
-
visa fler...
-
- Schjesvold, Fredrik (författare)
- Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway.;Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway.
-
- Abildgaard, Niels (författare)
- Odense Univ Hosp, Dept Haematol, Odense, Denmark.;Univ Southern Denmark, Dept Clin Res, Odense, Denmark.
-
- Nahi, Hareth (författare)
- Karolinska Institutet
-
- Andersen, Niels Frost (författare)
- Aarhus Univ Hosp, Dept Haematol, Aarhus, Denmark.
-
- Vangsted, Annette Juul (författare)
- Rigshosp, Dept Haematol, Copenhagen, Denmark.
-
- Klausen, Tobias Wirenfeldt (författare)
- Herlev Hosp, Dept Haematol, Herlev, Denmark.
-
- Helleberg, Carsten (författare)
- Herlev Hosp, Dept Haematol, Herlev, Denmark.
-
- Carlson, Kristina (författare)
- Uppsala universitet,Hematologi
-
- Frolund, Ulf Christian (författare)
- Zealand Univ Hosp, Dept Haematol, Roskilde, Denmark.
-
- Axelsson, Per (författare)
- Helsingborg Hosp, Dept Haematol, Helsingborg, Sweden.
-
- Stromberg, Olga (författare)
- Karolinska Univ Hosp, Dept Haematol, Stockholm, Sweden.
-
- Blimark, Cecilie Hveding (författare)
- Sahlgrens Univ Hosp, Dept Haematol, Gothenburg, Sweden.
-
- Crafoord, Jacob (författare)
- Örebro Univ Hosp, Dept Haematol, Örebro, Sweden.
-
- Tsykunova, Galina (författare)
- Haukeland Hosp, Dept Haematol, Bergen, Norway.
-
- Eshoj, Henrik Rode (författare)
- Odense Univ Hosp, Qual Life Res Ctr, Dept Haematol, Odense, Denmark.;Odense Univ Hosp, Open Patient Data Explorat Network, OPEN, Odense, Denmark.
-
- Waage, Anders (författare)
- Norwegian Univ Sci & Technol, St Olavs Hosp, Dept Haematol, Trondheim, Norway.;Norwegian Univ Sci & Technol, Inst Clin & Mol Med, Trondheim, Norway.
-
- Hansson, Markus (författare)
- Skane Univ Hosp, Dept Haematol, Lund, Sweden.
-
- Gulbrandsen, Nina (författare)
- Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway.
-
visa färre...
-
Aalborg Univ Hosp, Dept Haematol, Molleparkvej 4, DK-9000 Aalborg, Denmark Vilnius Univ, Hosp Santaros Klin, Dept Haematol, Vilnius, Lithuania. (creator_code:org_t)
- 2021-10-11
- 2022
- Engelska.
-
Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 108:1, s. 34-44
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 -> 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86). Results Median time to progression (TTP) after randomisation was 25.1 months (22.5-NR) in the carfilzomib-dexamethasone maintenance group and 16.7 months (14.4-21.8) in the control group (HR 0.46, 95% CI 0.30-0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections. Conclusion In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- carfilzomib
- induction chemotherapy
- maintenance chemotherapy
- multiple myeloma
- salvage therapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gregersen, Henri ...
-
Peceliunas, Vald ...
-
Remes, Kari
-
Schjesvold, Fred ...
-
Abildgaard, Niel ...
-
Nahi, Hareth
-
visa fler...
-
Andersen, Niels ...
-
Vangsted, Annett ...
-
Klausen, Tobias ...
-
Helleberg, Carst ...
-
Carlson, Kristin ...
-
Frolund, Ulf Chr ...
-
Axelsson, Per
-
Stromberg, Olga
-
Blimark, Cecilie ...
-
Crafoord, Jacob
-
Tsykunova, Galin ...
-
Eshoj, Henrik Ro ...
-
Waage, Anders
-
Hansson, Markus
-
Gulbrandsen, Nin ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet